Novartis seeks approval for Multiple Sclerosis drug in EU and US

Novartis is seeking approval from EU and US for use of experimental multiple sclerosis therapy, siponimod, to treat secondary progressive forms of MS. Secondary progressive multiple sclerosis (SPMS) is where the disease causes continuous worsening of neurological function over time, independent of relapses. Most people with relapsing remitting forms of MS will eventually go on

Continue Reading

European Commission approved AZ’s treatment for locally advanced, unresectable NSCLC

AstraZeneca’s durvalumab has been approved in Europe for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC). The decision enables doctors to prescribe the drug for adults with stage III NSCLC whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy (CRT). The

Continue Reading

EMA approve UCB’s treatment Cimzia for psoriasis

European Medicines Agency has approved a label extension for UCB’s Cimzia allowing it to be used for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval makes Cimzia, the first Fc-free, PEGylated anti-TNF treatment option for use in moderate-to-severe plaque psoriasis “and marks the entry of UCB into immuno-dermatology, where

Continue Reading

Nice set to collaborate with Greater Manchester to improve health of locals

A partnership between Greater Manchester and NICE that was created with the aim of improving the health of the local population has been extended for another three years. A Memorandum of Understanding has been agreed between NICE, Health Innovation Manchester and The University of Manchester outlining a shared commitment to boosting health through research, informing

Continue Reading

Sanofi and Regeneron to receive review from EU regulators for Dupixent and Cemiplimab

Sanofi and Regeneron have announced that EU regulators have agreed to review Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma. The French pharmaceutical company is seeking approval for Dupixent as an supplementary maintenance treatment in certain adults and adolescents, aged 12 years old and higher, with inadequately controlled moderate-to-severe asthma. The drug

Continue Reading